Clinical Guidelines for Immune Signature-Based Evaluation of Persistent Fever Syndromes

Abstract

Persistent fever syndromes represent a diagnostic challenge in clinical practice, often requiring a comprehensive and mechanistically informed approach to uncover underlying etiologies. Immune signature-based evaluation is an emerging paradigm, leveraging advances in immunology and molecular diagnostics to enhance diagnostic precision and inform management strategies. This review systematically examines the clinical guidelines, recent evidence, and practical implications of immune signature-based evaluation for persistent fever syndromes, addressing epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, recent therapeutic advances, and consensus guideline recommendations for healthcare professionals.

Introduction

Persistent fever, defined as a fever lasting more than three weeks with no clear diagnosis after one week of inpatient investigation, remains a complex clinical entity. The differential diagnosis is broad, encompassing infectious, autoimmune, malignant, and autoinflammatory causes. Conventional approaches often yield limited diagnostic clarity, prompting the need for advanced methodologies. Immune signature-based evaluation, which involves profiling immune cell populations, cytokine patterns, and genetic predispositions, offers a promising avenue for targeted diagnosis and management, fostering a precision medicine approach in fever of unknown origin (FUO).

Epidemiology / Disease Burden

Persistent fever syndromes account for a significant proportion of hospital admissions, particularly in tertiary care settings. Studies report that up to 25% of patients with FUO remain undiagnosed after exhaustive evaluation. The incidence varies geographically, influenced by local epidemiology of infectious diseases, prevalence of autoimmune conditions, and access to advanced diagnostics. The burden is further compounded by prolonged hospital stays, increased healthcare costs, and risks of unnecessary empirical therapies, underscoring the imperative for more effective diagnostic strategies.

Pathophysiology

The pathogenesis of persistent fever syndromes is heterogeneous, reflecting an array of underlying mechanisms. Infections stimulate innate and adaptive immune responses, often characterized by distinct cytokine profiles and immune cell activation. Autoimmune and autoinflammatory disorders feature dysregulation of immune tolerance, aberrant activation of inflammasomes, and persistent cytokine release. Malignancies may drive fever through paraneoplastic cytokine production and immune dysregulation. Immune signature-based evaluation seeks to differentiate these mechanisms by characterizing biomarkers such as interleukin profiles, interferon signatures, and cell subset distributions, enabling pathophysiologically informed diagnosis.

Risk Factors

Risk factors for persistent fever syndromes include immunosuppression, recent travel to endemic areas, exposure to zoonotic sources, underlying autoimmune disease, malignancy, and genetic predispositions to autoinflammatory conditions. Iatrogenic factors, such as biologic immunomodulators, can unmask or exacerbate underlying immune dysregulation, further complicating the clinical picture. Recognizing patient-specific risk factors is essential for tailoring immune signature profiling and prioritizing differential diagnoses.

Clinical Features

Clinical presentation is often nonspecific, with fever as the predominant symptom. Associated features may include night sweats, weight loss, arthralgia, rash, and lymphadenopathy, varying based on the underlying etiology. Infections may present acutely with systemic features, while autoimmune and autoinflammatory syndromes often manifest with recurrent or persistent fever episodes, mucocutaneous findings, and organ-specific involvement. Detailed history and physical examination remain foundational, guiding the selection of targeted immune signature assays.

Diagnosis

Diagnostic evaluation begins with a thorough clinical assessment, laboratory investigations (CBC, inflammatory markers, liver and renal function tests), and targeted imaging (chest X-ray, abdominal ultrasound). Immune signature-based evaluation incorporates advanced diagnostics such as flow cytometry (lymphocyte and monocyte subsets), cytokine profiling (IL-1, IL-6, TNF-alpha, IFN-gamma), gene panels for autoinflammatory syndromes (e.g., MEFV, NLRP3), and transcriptomic analysis. These modalities facilitate differentiation between infectious, autoimmune, and malignant processes, improving diagnostic yield and minimizing unnecessary interventions. Integration of these tools into diagnostic algorithms is crucial for optimal patient care.

Treatment & Management

Management is etiology-specific, guided by the results of immune signature profiling. Infectious causes require targeted antimicrobial therapy, while autoimmune and autoinflammatory conditions may respond to corticosteroids, immunosuppressants, or targeted biologic agents (e.g., IL-1 or IL-6 inhibitors). Empirical therapy should be minimized to avoid masking diagnostic clues. Multidisciplinary collaboration, including infectious disease, rheumatology, and hematology specialists, is recommended for complex cases. Regular re-evaluation and close monitoring are essential, with therapy adjusted based on evolving clinical and immunological findings.

Recent Advances / Emerging Therapies

Recent advances include high-throughput immune profiling platforms, next-generation sequencing for genetic and transcriptomic analysis, and machine learning algorithms for integrating immune signatures into diagnostic workflows. Novel therapeutics, such as Janus kinase inhibitors and targeted cytokine antagonists, are being evaluated in clinical trials for refractory autoinflammatory syndromes. The application of precision immunomodulation based on specific immune signatures heralds a new era in the personalized management of persistent fevers, with the potential to improve outcomes and reduce unnecessary interventions.

Guideline Recommendations

Current guidelines from major societies, including the Infectious Diseases Society of America (IDSA) and the European League Against Rheumatism (EULAR), endorse a stepwise approach to persistent fever evaluation, emphasizing the integration of immune signature-based diagnostics in selected cases. Recommendations highlight the importance of thorough clinical assessment, judicious use of advanced immunological and molecular tests, and avoidance of empirical immunosuppression without clear diagnosis. Early involvement of multidisciplinary teams and consideration of rare autoinflammatory syndromes are also emphasized in updated protocols.

Conclusion

Immune signature-based evaluation represents a paradigm shift in the diagnostic approach to persistent fever syndromes, offering enhanced precision and clinically actionable insights. The integration of advanced immunological profiling, genetic analysis, and evidence-based guidelines enables clinicians to tailor diagnostic and therapeutic strategies to individual patient profiles. Ongoing research and collaborative guideline development will further refine these approaches, ultimately improving patient outcomes and resource utilization in the management of persistent fever syndromes.